Cypherpunk Technologies Shifts Focus to Cancer Drug After $37.8 Million Loss

Cypherpunk Technologies, the treasury company behind Zcash (ZEC) and backed by Cameron and Tyler Winklevoss, has announced a strategic pivot towards its cancer drug candidate following a substantial net loss of $37.8 million in the first half of 2026. The company has acknowledged that it may need to secure additional funding if the price of ZEC does not increase soon.

Despite holding ZEC assets valued at approximately $157 million, Cypherpunk's market valuation stands at just $74 million, resulting in a multiple-to-Net Asset Value (mNAV) of 0.47x. This situation reflects a broader trend where crypto treasury stocks are trading below their asset values. The company has also reported a significant decline in its stock price, losing 40% of its value this year alone.

Cypherpunk's cancer drug candidate, Sirexatamab, has faced challenges in clinical trials, failing to demonstrate significant efficacy in a Phase 2 study. However, the FDA has granted it fast track designation, which could expedite its regulatory review process. The company is exploring options to advance Sirexatamab, including potential partnerships or spinning it out into an independent entity.

As of June 30, 2026, Cypherpunk had only $7.6 million in cash, alongside a substantial accumulated deficit, raising concerns about its financial viability as it pursues an expensive FDA approval path for its drug.